Financings

DRI Healthcare Trust Announces Closing of US$250 Million of Senior Secured Notes

DRI Healthcare Closes $250M Debt Roll as Leverage Climbs and EBITDA Guidance Slips

By The Northwire Desk — AI Analysis Mar 25, 2026 · 13:37 DHT · 17.09

Executive Summary

DRI Healthcare Trust announced the closing of a previously priced US$250 million private placement of senior secured notes on March 25, 2026.
The issuance consists of two tranches: US$106 million at 5.35% maturing March 24, 2031, and US$144 million at 5.65% maturing March 24, 2033.
Interest is payable semi-annually. The notes are secured by substantially all company assets and rank pari-passu with the existing credit facility.
Net proceeds will be used to repay outstanding debt, cover transaction fees, and fund general corporate purposes.
The offering was completed under Rule 144A and Regulation S with qualified institutional buyers, with no new terms or pricing adjustments disclosed relative to the March 3, 2026 announcement.

Material Impact

The closing is purely administrative and executes a financing that was already priced and communicated to the market three weeks prior.
It removes execution risk associated with the funding but does not introduce new capital, alter the company's strategic trajectory, or change the previously disclosed use of proceeds.
The transaction successfully extends the company's debt maturity profile into the early 2030s, replacing shorter-term credit facility draws with longer-dated, fixed-rate obligations.
Given the prior disclosure, the market has already priced in the dilution of security interests and the interest expense impact. The news is expected and incremental, warranting a routine classification.

DHT · Price

Company Overview

DRI Healthcare Trust is a publicly traded healthcare royalty and streaming company that acquires royalty interests in pharmaceutical, biotech, and medical device products.
The company does not operate a single flagship project but manages a diversified portfolio of 28 royalty streams across 21 commercialized and late-stage products.
Recent strategic focus has shifted toward pre-approval and late-stage clinical royalties, highlighted by the Ekterly (KalVista) acquisition and the synthetic royalty on Viridian Therapeutics' veligrotug and VRDN-003 for Thyroid Eye Disease.
Management completed the internalization of its investment function in late 2025, terminating the external manager (Persis Capital) to capture projected long-term synergies.

More from